What is it about?
In this study, we develop a test that can predict whether a patient has prostate cancer and how aggressive that cancer is. This test combines clinical measurements, levels of four genes collected from a fraction of the urine, and levels of six peptides found in urine. We found that this test, deemed ‘ExoSpec’, has the potential to improve the pathway for men with a clinical suspicion of prostate cancer and could reduce the requirement for biopsies by 30%.
Featured Image
Photo by Luke Chesser on Unsplash
Why is it important?
Prostate cancer is one of the leading causes of cancer-related death in men in the world, but a large proportion of men that are diagnosed with prostate cancer do not have a form of the disease that will cause them long term harm. Therefore, there is a need to accurately predict the aggressiveness of the disease without taking an invasive biopsy.
Perspectives
This is the third in a series of three research articles that looks at combining different measurements from urine in prostate cancer to detect significant prostate cancer.
Professor Daniel S. Brewer
University of East Anglia
Read the Original
This page is a summary of: A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data, Cancers, April 2022, MDPI AG,
DOI: 10.3390/cancers14081995.
You can read the full text:
Contributors
The following have contributed to this page
